22 Jul Engage Bio
Posted at 18:02h
in
Will Olsen, CEO
Oct. 8 | 9:15am | FLW Ballroom F
San Carlos, CA
(Private)
Engage Bio is developing Tethosomes, a new class of non-viral genetic medicines engineered for potency, safety, and programmability. Tethosomes achieve over 100x higher expression than traditional DNA vectors. Further, Tethosomes evade detection by the innate immune system, finally enabling safe and redosable non-viral DNA therapies. The programmability and specificity of Tethosomes enable broad therapeutic applications ranging from gene replacement to cancer immunotherapy.
